Overview

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Sev

Status:
Completed

Trial end date:
2017-04-07

Target enrollment:

Participant gender:

Summary

Investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process in patients with severe haemophilia A

Phase:

Phase 1

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Factor VIII